Fiserv Inc. Common Stock vs 10X Genomics Inc — how do they compare? Fiserv Inc. Common Stock trades at $46.27 (market cap $24.81B), while 10X Genomics Inc trades at $71.84 (market cap $9.35B). The key difference: Fiserv Inc. Common Stock is far larger — about 2.7× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Fiserv Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiserv Inc. Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.
| FISV | TXG | |
|---|---|---|
Market Cap | $24.81B | $9.35B |
Volume | 4,091,234 | 4,039,449 |
Sector | Technology | Health |
52-Week High | $126.54 | $97.74 |
52-Week Low | $44.36 | $11.83 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $52.60B | $8.88B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.
The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Fiserv, Inc. is a global provider of payments and financial services technology, offering merchant acquiring, digital commerce, and financial solutions through its Merchant Solutions and Financial Solutions segments.
Read more on FISV →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →